BriaCell Therapeutics Corp News - BCT

BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update

BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting...

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 29, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities

Insiders intend to acquire up to approximately 10% of BriaCell’s basic common shares, or 1.59 million...

BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BCT News

BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities

BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

October is Breast Cancer Awareness Month – BriaCell is Advancing the Fight with its Immunotherapy

BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30

BCT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT) News

BriaCell Therapeutics Corp (BCT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BCT News

BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer

BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq

BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities

BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®

BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

October is Breast Cancer Awareness Month – BriaCell is Advancing the Fight with its Immunotherapy

BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30

BCT Discussion

Your Recent History